Clinical Context
We think this might be relevant to the clinical guidance for iRECIST (Immune Response Criteria).
Clinical Context
We think this might be relevant to the clinical guidance for iRECIST (Immune Response Criteria).
Clinical Context
We think this might be relevant to the clinical guidance for iRECIST (Immune Response Criteria).
IRECISTImmune Response Evaluation in Solid Tumors
Clinical pearl
Pseudoprogression occurs when an influx of immune cells into the tumor causes a temporary increase in size. iRECIST avoids premature discontinuation of potentially effective therapy.
Outcome Framework
Clinical Strategy
Immune Stable Disease. Continue current immunotherapy regimen.
Verified
Last Review: 2026
Last Comprehensive Review: 2026